Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QCC374 · 1 trial · 1 indication
Number of Participants with Adverse Events
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo comparator |
| QCC374 | EXPERIMENTAL | Single and multiple ascending doses of QCC374 |
| Name | Type | Description |
|---|---|---|
| QCC374 | DRUG | Single and multiple ascending doses of QCC374 |
| Placebo | DRUG | Placebo comparator |
Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Healthy male and female subjects age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory...
QCC374 is an investigational small molecule developed by Novartis AG. It has been studied in a first-in-human Phase 1 clinical trial in healthy adult subjects. No therapeutic indication for QCC374 has been disclosed, and the compound remains in early clinical development rather than being an approved medicine.
QCC374 is made and developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis sponsored the first-in-human study of the compound, which was conducted in the United Kingdom.
QCC374 is in Phase 1 development. Its only recorded clinical trial was a first-in-human Phase 1 study that has been completed. Because no later-stage trials have been reported, QCC374 is investigational and is not an approved therapy.
QCC374 has been evaluated in one clinical trial, NCT02245828, titled a first-in-human study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of QCC374. The Phase 1 trial enrolled 66 healthy subjects in the United Kingdom and is now completed.
The QCC374 Phase 1 trial NCT02245828 was a randomized, double-blind, placebo-controlled study of single and multiple ascending doses. It enrolled 66 healthy volunteers aged 18 years and older of any sex and was conducted in the United Kingdom. The study assessed safety, tolerability and pharmacokinetics.
QCC374 is not an approved medicine. It is an investigational small molecule that has completed a single Phase 1 first-in-human trial, so it remains in early clinical development. No regulatory approval for QCC374 has been granted for any indication.